Zhuotao Xiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhuotao Xiao has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Joris I. Rotmans
Department of Internal Medicine Leiden University Medical Center (LUMC) Leiden The Netherlands
3 shared publications Anton Jan van Zonneveld
Department of Internal Medicine (Nephrology) and the Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, 2333, ZA, Netherlands
1 shared publication- Asad Mirza
Department of Biomedical Engineering, Florida International University, Miami, FL, 33199, United States
1 shared publication - Bernard M. van Den Berg
Department of Internal Medicine (Nephrology) & Einthoven Laboratory of Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands
1 shared publication Huybert J.F. van de Stadt
Department of Medical Technology, Design & Prototyping, Leiden University Medical Center, Leiden, 2333, ZA, Netherlands
1 shared publicationJun Wen
Department of Computer Science and Technology, Southwest University of Science and Technology, Mianyang, 621010, China
1 shared publication
Latest Publications
- Open Access
- 13 June 2024
- Published by Elsevier in Materials Today Bio
- Vol. 27, 101121
A bypass flow model to study endothelial cell mechanotransduction across diverse flow environments
- 13 June 2024
- Published by Elsevier in Materials Today Bio
- Vol. 27, 101121
Open AccessA bypass flow model to study endothelial cell mechanotransduction across diverse flow environments
- 7 November 2023
- Published by SAGE Publications in The Journal of Vascular Access
- Vol. 25 (6) , 1749-1756
Outcomes of early cannulation arteriovenous graft versus PTFE arteriovenous graft in hemodialysis patients: A meta-analysis and systematic review
Arteriovenous graft (AVG) is an alternative for hemodialysis (HD) patients with end-stage renal disease when their permanent vascular accesses fail. Since the last decades, the most widely used materials in these patients have been polytetrafluoroethylene (PTFE)-AVGs. Recently, several studies have reported that early cannulation (EC)-AVG can be an alternative to PTFE-AVG. This systematic review and meta-analysis aimed to compare the outcomes of EC-AVG and PTFE-AVG in HD patients. We searched the Ovid Embase, Ovid MEDLINE, and Cochrane Central Register of Controlled Trials for the relevant studies published from 01.01.2000 to 19.12.2022 by keywords and free words. All randomized controlled trials (RCTs) and observational cohort studies comparing EC-AVG with PTFE-AVG were included. Ten studies were included in analysis: one RCT, six retrospective cohort studies, and three prospective cohort studies. The results showed shorter cannulation intervals (four studies, 1116 participants: mean difference −23.62 days, 95% CI [−32.03, −15.21], p < 0.05) and less central venous catheter (CVC) usage (four studies, 733 participants: OR 0.20, 95% CI [0.04, 0.92], p < 0.05) for EC-AVG compared with PTFE-AVG, while comparable outcomes of primary patency (eight studies, 1712 participants: HR 0.89, 95% CI [0.70, 1.12]), primary assisted patency (five studies, 1355 participants: HR 1.13, 95% CI [0.70, 1.84]), secondary patency (nine studies, 1920 participants: HR 0.93, 95% CI [0.66, 1.31]), and infection risk (four studies, 640 participants: HR 1.12, 95% CI [0.48, 2.58]). When compared to PTFE-AVG in HD patients, EC-AVG seems to exhibit shorter cannulation intervals, less CVC usage, and comparable outcomes of graft patency, and infection risk.
- 7 November 2023
- Published by SAGE Publications in The Journal of Vascular Access
- Vol. 25 (6) , 1749-1756
Outcomes of early cannulation arteriovenous graft versus PTFE arteriovenous graft in hemodialysis patients: A meta-analysis and systematic review
Arteriovenous graft (AVG) is an alternative for hemodialysis (HD) patients with end-stage renal disease when their permanent vascular accesses fail. Since the last decades, the most widely used materials in these patients have been polytetrafluoroethylene (PTFE)-AVGs. Recently, several studies have reported that early cannulation (EC)-AVG can be an alternative to PTFE-AVG. This systematic review and meta-analysis aimed to compare the outcomes of EC-AVG and PTFE-AVG in HD patients. We searched the Ovid Embase, Ovid MEDLINE, and Cochrane Central Register of Controlled Trials for the relevant studies published from 01.01.2000 to 19.12.2022 by keywords and free words. All randomized controlled trials (RCTs) and observational cohort studies comparing EC-AVG with PTFE-AVG were included. Ten studies were included in analysis: one RCT, six retrospective cohort studies, and three prospective cohort studies. The results showed shorter cannulation intervals (four studies, 1116 participants: mean difference −23.62 days, 95% CI [−32.03, −15.21], p < 0.05) and less central venous catheter (CVC) usage (four studies, 733 participants: OR 0.20, 95% CI [0.04, 0.92], p < 0.05) for EC-AVG compared with PTFE-AVG, while comparable outcomes of primary patency (eight studies, 1712 participants: HR 0.89, 95% CI [0.70, 1.12]), primary assisted patency (five studies, 1355 participants: HR 1.13, 95% CI [0.70, 1.84]), secondary patency (nine studies, 1920 participants: HR 0.93, 95% CI [0.66, 1.31]), and infection risk (four studies, 640 participants: HR 1.12, 95% CI [0.48, 2.58]). When compared to PTFE-AVG in HD patients, EC-AVG seems to exhibit shorter cannulation intervals, less CVC usage, and comparable outcomes of graft patency, and infection risk.
- Open Access
- 1 August 2023
- Published by Wolters Kluwer Health in Kidney360
- Vol. 4 (8) , 1019-1020
Considering the Closure of Arteriovenous Fistulas in Kidney Transplant Recipients
- 1 August 2023
- Published by Wolters Kluwer Health in Kidney360
- Vol. 4 (8) , 1019-1020
Open AccessConsidering the Closure of Arteriovenous Fistulas in Kidney Transplant Recipients